BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
US Army
Julphar
Citi
Cerilliant
Queensland Health
Fuji
Daiichi Sankyo
Covington

Generated: January 22, 2018

DrugPatentWatch Database Preview

Rempex Pharms Medcns Company Profile

« Back to Dashboard

What is the competitive landscape for REMPEX PHARMS MEDCNS, and what generic alternatives to REMPEX PHARMS MEDCNS drugs are available?

REMPEX PHARMS MEDCNS has one approved drug.

There are two US patents protecting REMPEX PHARMS MEDCNS drugs.

There are seventeen patent family members on REMPEX PHARMS MEDCNS drugs in fourteen countries.

Summary for Rempex Pharms Medcns
International Patents:17
US Patents:2
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Rempex Pharms Medcns

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rempex Pharms Medcns VABOMERE meropenem; vaborbactam POWDER;IV (INFUSION) 209776-001 Aug 29, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Rempex Pharms Medcns VABOMERE meropenem; vaborbactam POWDER;IV (INFUSION) 209776-001 Aug 29, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Rempex Pharms Medcns

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,296,763 Cyclic boronic acid ester derivatives and therapeutic uses thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Rempex Pharms Medcns Drugs

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Argus Health
US Army
Daiichi Sankyo
Cerilliant
Deloitte
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot